Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTBTDM1)

DTT Name TNF-related weak inducer of apoptosis (TWEAK)
Synonyms Tumor necrosis factor ligand superfamily member 12; TWEAK; DR3LG; APO3L; APO3 ligand
Gene Name TNFSF12
DTT Type
Clinical trial target
 [1]
BioChemical Class
Cytokine: tumor necrosis factor
UniProt ID
TNF12_HUMAN
TTD ID
T46524
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
Sequence
MAARRSQRRRGRRGEPGTALLVPLALGLGLALACLGLLLAVVSLGSRASLSAQEPAQEEL
VAEEDQDPSELNPQTEESQDPAPFLNRLVRPRRSAPKGRKTRARRAIAAHYEVHPRPGQD
GAQAGVDGTVSGWEEARINSSSPLRYNRQIGEFIVTRAGLYYLYCQVHFDEGKAVYLKLD
LLVDGVLALRCLEEFSATAASSLGPQLRLCQVSGLLALRPGSSLRIRTLPWAHLKAAPFL
TYFGLFQVH
Function
Binds to FN14 and possibly also to TNRFSF12/APO3. Weak inducer of apoptosis in some cell types. Mediates NF-kappa-B activation. Promotes angiogenesis and the proliferation of endothelial cells. Also involved in induction of inflammatory cytokines. Promotes IL8 secretion.
Reactome Pathway
TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway (R-HSA-5676594 )
TNFR2 non-canonical NF-kB pathway (R-HSA-5668541 )

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DTT
2 Clinical Trial Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
BIIB 023 DM9OXEJ Rheumatoid arthritis FA20 Phase 2 [1]
RO-5458640 DMVXQ5W Solid tumour/cancer 2A00-2F9Z Phase 1 [2]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT00771329) BIIB023 (Anti-TWEAK) in Subjects With Rheumatoid Arthritis. U.S. National Institutes of Health.
2 A novel llama antibody targeting Fn14 exhibits anti-metastatic activity in vivo. MAbs. 2014 January 1; 6(1): 297-308.